We Target Chronic Inflammation
Recognizing the link between inflammation and numerous chronic diseases, Halia is pioneering targeting a specific inflammatory pathway, NLRP3, with an allosteric inhibitor to disrupt chronic inflammation. The goal of this method is to reduce inflammation and help reset this inflammatory pathway, potentially treating neurodegeneration and inflammatory diseases to improve quality of life and promote longevity.
Obesity
Almost half of US adults are obese or severely obese. Lack of physical activity, unhealthy eating behavior, and, in some cases, genetics contribute to obesity. Halia is developing investigational treatments to combat obesity.
Pain and Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is an autoimmune condition where the immune system—normally the body's defender against infection and disease—attacks its own tissues. This results in pain, swelling, stiffness, and loss of joint function. Halia is developing an investigational treatment for both RA and post-surgical pain.
Alzheimer's Disease
Alzheimer’s disease involves parts of the brain that control memory, language, problem-solving, and other thinking abilities. It can seriously affect a person’s ability to carry out daily activities. Halia is developing a potentially relevant pathway and investigational treatment for Alzheimer’s.
Parkinson's Disease
Parkinson’s disease is a progressive disorder that affects the nervous system and the parts of the body controlled by the nerves. Tremors, stiffness, or slowing of movement are typical symptoms. Halia is developing a potential brain-penetrant compound to treat the disease.
Cancer
Live Better, Longer
We recognize that patients want to improve their health. Halia is dedicated to disrupting chronic inflammation to treat or prevent neurodegeneration and inflammatory diseases to improve quality of life and promote longevity.
NLRP3 Inflammasome:
Our drug targets to disrupt
chronic inflammation
Inflammation is an essential biological response of the human immune system that protects against disease. However, when dysregulated, inflammation can become a driver of disease by promoting a persistent, systemic immune response that fuels the development of many chronic diseases.1
One of the primary mechanisms mediating the persistent, systemic inflammatory response is activating a large protein complex called the NLRP3 inflammasome. The inflammasome activation produces pro-inflammatory signaling proteins, which contribute considerably to disease-causing inflammation.2
Science for longevity and quality of life
Our founders are renowned scientists with experience in drug discovery for oncology and neurodegeneration. We have made fundamental discoveries, identifying drug candidates that may potentially treat multiple disorders, including Alzheimer’s disease and other neurodegenerative disorders, as well as cancers and obesity.
Be a part of health history:
Schedule a meeting
Contact us
Participate in a trial
In the News
Halia Therapeutics to Attend the 43rd J.P. Morgan Healthcare Conference and Present at BioPharma Obesity Innovation Forum in San Francisco
LEHI, Utah, Jan. 8, 2025 /PRNewswire/ -- Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today that its leadership team will attend and participate in a panel discussion during the 43nd J.P. Morgan Healthcare Conference (January 13 – 16, 2025), and will also present at the 1st Annual BioPharma...
M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE
Trial underscores IROS's commitment to developing innovative therapies for unmet medical needs January 7, 2025 The study’s success could transform obesity treatment globally Positions the UAE as a hub for cutting-edge clinical research Abu Dhabi, UAE: To combat a global obesity epidemic that is placing significant strain on healthcare systems worldwide, IROS, an Abu Dhabi-based contract...
BioWorld Appointments and advancements for January 6, 2025
See today's BioWorld New hires and promotions in the biopharma industry, including: Amylyx, Beigene, Blossomhill, Halia, Iambic, Perspective, Portage, Septerna, Unity. Amylyx Pharmaceuticals Inc., of Cambridge, Mass., named Dan Monahan chief commercial officer. Beigene Ltd., of Basel, Switzerland, appointed Giancarlo Benelli senior vice president and head of Europe. Blossomhill Therapeutics...